Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CD38 | P28907 | 11/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RBP4 | P02753 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335881 | 1.00 | HTT (0.49) | HTTCD38MAPTRBP4CYP2C19 | |
| SCHEMBL25485897 | 0.86 | KDM4E (0.45) | CD38MAPTCYP2C19CYP2D6CYP2B6 | |
| SCHEMBL31005861 | 0.85 | L3MBTL1 (0.41) | HTTCD38RBP4CYP2C19CYP1A2 | |
| SCHEMBL25189627 | 0.84 | CD38 (0.46) | CD38RBP4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL30261776 | 0.84 | CD38 (0.46) | CD38RBP4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL3559627 | 0.84 | CD38 (0.46) | CD38CYP2C19CYP1A2NOS2 | |
| SCHEMBL3566113 | 0.83 | CD38 (0.45) | CD38CYP2C19CYP2D6CYP1A2NOS2 | |
| SCHEMBL25187654 | 0.83 | HTT (0.46) | HTTCD38MAPTCYP2C19CYP2D6 | |
| SCHEMBL31005860 | 0.83 | HTT (0.46) | HTTCD38MAPTCYP2C19CYP2D6 | |
| SCHEMBL3558150 | 0.82 | CD38 (0.47) | CD38CYP2C19CYP2D6CYP2B6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019369-A1 | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as CD38 inhibitors | Cerevance, Inc. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4430034-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | Cerevance, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118317955-A | N- (4-aminocyclohexyl) pyrimidine-4-carboxamide as CD38 inhibitor | 塞里文斯股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023084206-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | CEREVANCE LTD (GB) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019369-A1 | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as CD38 inhibitors | CD38, CXCR4, P2RY1 | HTT 2007/4885CD38 1/4885MAPT 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.